Last reviewed · How we verify
Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is a Biologic drug developed by Sanofi. It is currently in Phase 2 development. Also known as: Menactra®, DAPTACEL®, IPOL.
At a glance
| Generic name | Polysaccharide Diphtheria Toxoid Conjugate Vaccine |
|---|---|
| Also known as | Menactra®, DAPTACEL®, IPOL |
| Sponsor | Sanofi |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PHASE1)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa (PHASE3)
- A Study on the Safety and Immune Responses to the GVGH altSonflex1-2-3 Vaccine Against Shigellosis in Adults, Children, and Infants (PHASE1)
- A Study to Evaluate Safety, Reactogenicity, and Immune Response of GVGH iNTS-TCV Vaccine Against Invasive Nontyphoidal Salmonella and Typhoid Fever (PHASE1, PHASE2)
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand (PHASE3)
- Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age (PHASE3)
- Study on a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Compared to a Meningococcal Reference Vaccine, and When Given Alone or With Two Other Vaccines in Healthy Adolescents (PHASE3)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine CI brief — competitive landscape report
- Polysaccharide Diphtheria Toxoid Conjugate Vaccine updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Polysaccharide Diphtheria Toxoid Conjugate Vaccine
What is Polysaccharide Diphtheria Toxoid Conjugate Vaccine?
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is a Biologic drug developed by Sanofi.
Who makes Polysaccharide Diphtheria Toxoid Conjugate Vaccine?
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
Is Polysaccharide Diphtheria Toxoid Conjugate Vaccine also known as anything else?
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is also known as Menactra®, DAPTACEL®, IPOL.
What development phase is Polysaccharide Diphtheria Toxoid Conjugate Vaccine in?
Polysaccharide Diphtheria Toxoid Conjugate Vaccine is in Phase 2.
Related
- Manufacturer: Sanofi — full pipeline
- Also known as: Menactra®, DAPTACEL®, IPOL
- Compare: Polysaccharide Diphtheria Toxoid Conjugate Vaccine vs similar drugs
- Pricing: Polysaccharide Diphtheria Toxoid Conjugate Vaccine cost, discount & access